Noninvasive early prediction of preeclampsia in pregnancy using retinal vascular features

• Published in: NPJ digital medicine Vol. 8; no. 1; pp. 188 - 9
• Main Authors: Wu, Yuxuan, Shen, Lixia, Zhao, Lanqin, Lin, Xiaohong, Xu, Miaohong, Tu, Zhenjun, Huang, Yihong, Kong, Lingyi, Lin, Zhenzhe, Lin, Duoru, Liu, Lixue, Wang, Xun, Cao, Zizheng, Chen, Xi, Zhou, Shengmei, Hu, Weiling, Huang, Yunjian, Chen, Shiyuan, Dongye, Meimei, Zhang, Xulin, Wang, Dongni, Shi, Danli, Wang, Zilian, Wu, Xiaohang, Wang, Dongyu, Lin, Haotian
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05.04.2025; Nature Publishing Group; Nature Portfolio
• Subjects: 692/53/2423; 692/699/75/243/793; Artificial intelligence; Biomarkers; Biomedicine; Biotechnology; Clinical medicine; Gestational age; Hospitals; Hypertension; Kidney diseases; Machine learning; Medicine; Medicine & Public Health; Mortality; Obstetrics; Ophthalmology; Overweight; Preeclampsia; Pregnancy; Prenatal care; Regression analysis; Risk factors; Womens health; Hong Kong China; China
• DOI: 10.1038/s41746-025-01582-6
• ISSN: 2398-6352

Preeclampsia (PE), a severe hypertensive disorder during pregnancy, significantly contributes to maternal and neonatal mortality. Existing prediction biomarkers are often invasive and expensive, hindering their widespread application. This study introduces PROMPT (Preeclampsia Risk factor + Ophthalmic data + Mean arterial pressure Prediction Test), an AI-driven model leveraging retinal photography for PE prediction, registered at ChiCTR (ChiCTR2100049850) in August 2021. Analyzing 1812 pregnancies before 14 gestational weeks, we extracted retinal parameters using a deep learning system. The PROMPT achieved an AUC of 0.87 (0.83–0.90) for PE prediction and 0.91 (0.85–0.97) for preterm PE prediction using machine learning, significantly outperforming the baseline model ( p  < 0.001). It also improved detection of severe adverse pregnancy outcomes from 35% to 41%. Economically, PROMPT was estimated to avert 1809 PE cases and saved over $50 million per 100,000 screenings. These results position PROMPT as a non-invasive and cost-effective tool for prenatal care, especially valuable in low- and middle-income countries.